The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse

Abstract Background The plasma cell malignancy multiple myeloma (MM) remains incurable due to the inevitable development of drug resistance (DR). Epigenetic modifiers are frequently mutated or deregulated in MM patients, contributing to MM progression and relapse. Overexpression of the de novo DNA m...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Catharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, Robbe Heestermans, Hatice Satilmis, Emma Verheye, Elina Alaterre, Catharina Olsen, Nathan De Beule, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2025-04-01
Rangatū:	Journal of Experimental & Clinical Cancer Research
Ngā marau:	Multiple myeloma Epigenetics DNMT3B Relapse
Urunga tuihono:	https://doi.org/10.1186/s13046-025-03382-y
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!